BCL2 and laryngeal carcinoma: MiR-34c inhibits Bcl2 by pairing to the 3′ untranslated region (UTR) of Bcl2 gene, thus down-regulating the viability of laryngeal cancer cells and inducing apoptosis in them [6], and it enhances the cell sensitivity to cisplatin by suppressing the SOX9/β-catenin/c-Myc pathway.